person · Reporting owner
DE SCHUTTER RICHARD U
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch & Lomb CorpBLCO · Entity 3756 | Director | March 29, 2024 | April 02, 2024 |
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | March 31, 2023 | April 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch & Lomb Corp
Report date March 29, 2024 · Filed April 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 32,952 |
Reported balance
After 2024-03-29 transaction · row 1
1 source rowRow 1 · 2024-03-29 · Grant · Acquired 1,553 · Balance 32,952 F1: Reflects restricted share units, each representing a contingent right to receive one common share, no par value, of Bausch + Lomb Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted share units, each representing a contingent right to receive one common share, no par value, of Bausch + Lomb Corporation.
Bausch Health Companies Inc.
Report date March 31, 2023 · Filed April 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 373,407 |
Reported balance
After 2023-03-31 transaction · row 1
1 source rowRow 1 · 2023-03-31 · Grant · Acquired 3,642 · Balance 373,407 F1: Reflects Restricted Share Units, each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. |
| Common Shares, No Par ValueSEC Table I · non-derivative | IndirectBy spouse | 13,800 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Restricted Share Units, each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2017 Filed May 15, 2017 21:19 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | PurchaseCommon Stock, No Par Value | 20,000 | $13.90 | $278,000.00 |
DisclosureSEC source: 0001127602-17-018110 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,572 F1 · price: Represents volume-weighted average price of purchases of 20,000 shares of common stock ("Shares") of Valeant Pharmaceuticals International, Inc. (the "Company") at prices ranging from $13.88 to $13.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of Shares purchased by the reporting person at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2017 Filed May 8, 2017 20:52 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, no par value | 2,148 | $9.66 | $20,749.68 |
DisclosureSEC source: 0000885590-17-000034 · primary_doc.xml · nonDerivative · entry 2 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,572 F2 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| May 05, 2017 Filed May 8, 2017 20:52 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 25,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000885590-17-000034 · primary_doc.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,720 F1 · shares: Regular annual Restricted Share Units (RSUs) equal to $250,000 granted to non-employee directors in office on the third trading day following the Annual Meeting of Shareholders based on the closing price of registrant common stock on the date prior to the grant. RSUs represent a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:47 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 2,124 | $11.03 | $23,427.72 |
DisclosureSEC source: 0000885590-17-000020 · primary_doc.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,314 F1 · shares: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 21:12 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | PurchaseCommon Stock, no par value | 10,000 | $10.80 | $108,000.00 |
DisclosureSEC source: 0000885590-17-000018 · primary_doc.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,190 F1 · shares: Represents volume-weighted average price of purchases of 10,000 shares of common stock (Shares) of Valeant Pharmaceuticals International, Inc. (the Company) at prices ranging from $10.79 to $10.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of Shares purchased by the reporting person at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:13 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 11,190 | $15.24 | $170,535.60 |
DisclosureSEC source: 0001681871-17-000003 · primary_doc.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,190 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. F2 · shares: Prorated annual grant of restricted stock units equal to $170,547.95. Pricing is based on the closing price of registrant common stock on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.